Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Tuesday, March 1, 2022
According to findings from an updated safety analysis of the multicenter, open-label, phase III CANDOR trial, presented in The Lancet Oncology, addition of the monoclonal antibody daratumumab to the combination of carfilzomib and dexamethasone (KdD) continues to be more efficacious than carfilzomib and dexamethasone alone in the treatment of patients with relapsed or refractory multiple myeloma. These updated results support the initial findings from the CANDOR study.
“This study confirms the favorable benefit-risk profile and advantages of continued treatment with [carfilzomib/daratumumab/dexamethasone] and represents an emerging standard of care in the management of patients with relapsed or refractory multiple myeloma, especially those previously exposed or refractory to lenalidomide,” concluded Meletios Dimopoulos, MD, of National and Kapodistrian University of Athens in Greece, and colleagues.
Between June 13, 2017, and June 25, 2018, a total of 466 patients were assigned to receive either KdD (n = 312) or carfilzomib and dexamethasone alone (n = 154). At an extended follow-up of 27.8 months in the triplet-therapy group and 27.0 months in the dual-therapy group, median progression-free survival was 28.6 months versus 15.2 months, respectively. The initial analysis of the CANDOR results at a median follow-up of approximately 17 months found that the median progression-free survival was not reached in the triplet-therapy group and 15.8 months in the dual-therapy group.
Treatment-emergent adverse events grade 3 or higher were experienced by 87% (n = 267) of patients receiving the triplet regimen and 76% (n = 116) of patients receiving dual therapy, with the most commonly occurring event being thrombocytopenia, hypertension, pneumonia, and anemia. A total of 27 patients receiving the triple therapy and 7 patients receiving dual therapy experienced adverse events resulting in death. All recorded treatment-related deaths occurred during the primary analysis.
Disclosure: For full disclosures of the study authors, visit thelancet.com.
JNCCN Spotlights
